Squarepoint
CARM

Squarepoint’s Carisma Therapeutics CARM Stock Holding History

Squarepoint’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,354
Closed -$69K – 3185
2021
Q3 		$69K Buy
+4,354
New +$209K ﹤0.01% 2736
2021
Q2 		– Sell
-2,108
Closed -$110K – 3259
2021
Q1 		$110K Buy
+2,108
New +$99.5K ﹤0.01% 2875
2020
Q4 		– Sell
-9,770
Closed -$274K – 2942
2020
Q3 		$274K Buy
9,770
+9,178
+1,550% +$184K ﹤0.01% 1866
2020
Q2 		$9K Buy
+592
New +$7.98K ﹤0.01% 2166
2018
Q4 		– Sell
-672
Closed -$29K – 1957
2018
Q3 		$29K Buy
+672
New +$26.2K ﹤0.01% 1934
2018
Q2 		– Sell
-1,914
Closed -$40K – 1761
2018
Q1 		$40K Buy
+1,914
New +$36.7K ﹤0.01% 1618
2015
Q3 		– Sell
-570
Closed -$32K – 426
2015
Q2 		$32K Buy
+570
New +$80.5K 0.01% 435

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Squarepoint's CARM Position: Q4 2021 in Review

Squarepoint sold out of Carisma Therapeutics (CARM) in Q4 2021, closing a stake of 4,354 shares — an estimated $69K sold.

Squarepoint first reported a position in CARM in Q2 2015 and held it in 7 quarters. The position peaked at $274K in Q3 2020. 93 funds tracked by Wall St. Rank hold CARM as of Q4 2021.

  • Squarepoint reported no remaining Carisma Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Squarepoint sold 4,354 Carisma Therapeutics shares in Q4 2021, an estimated $69K.
  • Squarepoint first reported a position in Carisma Therapeutics in Q2 2015 and held it in 7 quarters.
  • Squarepoint's Carisma Therapeutics position peaked at $274K in Q3 2020.
  • 93 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.